FierceBiotechOriginal article
{"a":[{"_":"Amgen abandoning $500M+ Crohn’s collab won’t derail TScan’s pipeline strategy","$":{"href":"/biotech/amgen-abandons-500m-inflammation-team-tscan-therapeutics","hreflang":"en"}}]}
PartnershipnegativeNegative
AI Analysis
Summary
Amgen has abandoned a Crohn's disease collaboration with TScan Therapeutics that was worth more than $500 million. TScan stated its pipeline strategy remains unchanged despite the partnership termination.
Outcome Details
Amgen abandoned Crohn's disease collaboration with TScan worth $500M+
Importance:5/10
Sentiment:
-0.40
partnership dissolutionCrohn's diseasecollaboration termination
Related Companies
Read the original article
Published by FierceBiotech on August 19, 2026 5:32 PM